Driehaus Capital ILMN Position
Exited5-Fund ConvergenceDriehaus Capital exited their position in Illumina Inc. (ILMN) in Q1 2025, after holding the stock for 3 quarters.
The position was first reported in Q3 2024 and has been tracked across 3 quarterly 13F filings.
ILMN is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Full company profile →Short Interest
7.4%
3.6 days to cover
Driehaus Capital ILMN Position History
Frequently Asked Questions
Does Driehaus Capital own ILMN?
No. Driehaus Capital exited their position in Illumina Inc. (ILMN) in Q1 2025. They previously held the stock for 3 quarters.
How many hedge funds own ILMN?
5 specialist biotech hedge funds currently hold ILMN, including Casdin Capital, RTW Investments, Perceptive Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy ILMN?
Driehaus Capital's position in ILMN was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's ILMN position increasing or decreasing?
Driehaus Capital completely exited their ILMN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ILMNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →